Reversal or nitroglycerin tolerance by the cGMP phosphodiesterase inhibitor zaprinast.
Silver
P J
PJ
Department of Cardiovascular Pharmacology, Sterling Research Group, Rensselaer, NY 12144.
Pagani
E D
ED
de Garavilla
L
L
Van Aller
G S
GS
Volberg
M L
ML
Pratt
P F
PF
Buchholz
R A
RA
D015106:3',5'-Cyclic-GMP Phosphodiesterases / Q000037:antagonists & inhibitors*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D004361:Drug Tolerance; D066298:In Vitro Techniques; D008297:Male; D009126:Muscle Relaxation / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects*; D005996:Nitroglycerin / Q000494:pharmacology*; D011688:Purinones / Q000494:pharmacology*; D051381:Rats; D011919:Rats, Inbred Strains
D011688:Purinones; D015106:3',5'-Cyclic-GMP Phosphodiesterases; D005996:Nitroglycerin; C011145:zaprinast